Company intelligence / Profile preview

AdCella

Regensburg, Bavaria, Germany

Ownership: Private
Development stage: Other

Overview

AdCella was a German biotechnology company focused on the development and commercialization of adipose-derived regenerative cell (ADRC) therapies. The company utilized a proprietary point-of-care process to isolate high-quality stem and progenitor cells from a patient's own adipose tissue. These autologous cells were primarily targeted for applications in regenerative medicine, including the treatment of chronic wounds and reconstructive surgery. AdCella's technology aimed to provide a standardized, rapid, and efficient method for cell transplantation without the need for external laboratory cultivation.

Therapeutic areas: OtherDermatology
Modalities: Cell therapyStem cell therapy
Industry: Biotech

Drug pipeline

2 assets

Y-CAR-T

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on AdCella.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdCella.

Explore the full profile